Flagship Biosciences pathologists present two posters using quantitative pathology techniques in oncology research at the American Association for Cancer Research.
Flagstaff, AZ – April 17, 2010 – Flagship Biosciences LLC,(Flagship) will present two posters at the Flagship Biosciences to present at the American Heart Association Boulder, CO – December 6, 2009 – Flagship Biosciences LLC,(Flagship) will present the use of digital pathology in morphometric analysis of heart infarct tissue at the American Heart Association annual meeting in Miami Florida. The presentation is titled Antibody to Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Number of Activated Tissue Macrophages and Improves Left Ventricular Function Following Myocardial Infarction in a Rat Coronary-Artery Ligation Model Flagship Biosciences is a pathologist-owned company focused on utilizing whole slide imaging for quantitative pathology in pharmaceutical and device applications. American Association for Cancer Research meeting in Washington DC. The first, with Dr. David Young, is titled “Evaluating epithelial-to-mesenchymal transition (EMT) in the EL1-luc/EL1-SV40 T-antigen transgenic mouse model of pancreatic cancer.” The lead author is Dr. Maryland Rosenfeld Franklin from OSI Pharmaceuticals. The second, with Dr. Frank Voelker, is titled The Hh inhibitor IPI-926 inhibits relapse of a non-small cell lung cancer xenograft model following treatment with an EGF-R targeted tyrosine kinase inhibitor. The lead author is Everton Mandley from Infinity Pharmaceuticals.
Flagship Biosciences is a pathologist-owned company focused on utilizing whole slide imaging for quantitative pathology in pharmaceutical and device applications.
